Angelini Pharma is pleased to announce the appointment of Rafal Kaminski as Chief Scientific Officer. He will join the Company on January 17th.
Kaminski has broad international experience primarily focused on the discovery and development of innovative small molecule drugs. After obtaining medical degree and doctorate in pharmacology at the Medical University of Lublin (Poland), he completed his post-doctoral training in the Netherlands (Radboud University) and USA (National Institutes of Health), as well as obtained the Diploma in Pharmaceutical Medicine (ULB, Belgium).
Kaminski joined pharmaceutical industry 15 years ago and held various R&D roles of increasing responsibility at UCB Pharma (Belgium) and Roche (Switzerland).
Prior to joining Angelini Pharma he has led the entire R&D organization, spanning from discovery to clinical development and served as Chief Scientific Officer and Board Member of OncoArendi Therapeutics, a leading biotech company in Poland. He also has experience in coordination and oversight of drug discovery projects performed in collaboration with world-class academic partners and CROs.